In vitro, classical complement activation differs by disease severity and between SARS-CoV-2 antigens
暂无分享,去创建一个
I. Henderson | M. Drayson | A. Cunningham | S. Faustini | M. Crispin | T. Veenith | S. Watson | J. Rayes | A. Shields | A. Richter | D. Wraith | M. Pérez-Toledo | I. Chapple | S. Jossi | M. Newby | T. Dietrich | L. Harper | M. Goodall | R. Lamerton | E. Marcial Juarez | S. P. Watson
[1] A. Cunningham,et al. Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic , 2021, Journal of Molecular Biology.
[2] J. Heeney,et al. Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins , 2021, Frontiers in Immunology.
[3] M. Drayson,et al. COVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals , 2021, Journal of dental research.
[4] M. Drayson,et al. Development of a high‐sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS‐CoV‐2 spike glycoprotein in serum and saliva , 2021, Immunology.
[5] C. Powell,et al. Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease , 2021, Journal of clinical medicine.
[6] S. Thiel,et al. Plasma Lectin Pathway Complement Proteins in Patients With COVID-19 and Renal Disease , 2021, Frontiers in Immunology.
[7] A. Darby,et al. Covid-19: variants and vaccination , 2021, BMJ.
[8] J. Atkinson,et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. , 2021, bioRxiv.
[9] B. Payne,et al. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection , 2020, Journal of Infection.
[10] D. Stuart,et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.
[11] J. Beeson,et al. Complement Factors in COVID-19 Therapeutics and Vaccines , 2020, Trends in Immunology.
[12] M. Drayson,et al. Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients , 2020, Journal of Immunological Methods.
[13] M. Drayson,et al. Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response , 2020, medRxiv.
[14] Shruti Chaturvedi,et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition , 2020, Blood.
[15] John D Lambris,et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis , 2020, medRxiv.
[16] Ilya J. Finkelstein,et al. Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes , 2020, bioRxiv.
[17] Leora I. Horwitz,et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study , 2020, BMJ.
[18] David Berlin,et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases , 2020, Translational Research.
[19] O. Tsang,et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.
[20] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[21] Piet Gros,et al. Complement Is Activated by IgG Hexamers Assembled at the Cell Surface , 2014, Science.
[22] P. Horby,et al. Edinburgh Research Explorer Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020 .
[23] Wen-chao Song,et al. Complement and its role in innate and adaptive immune responses , 2010, Cell Research.